Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacidophilin
- Development stage
- Unknown
- Lead developer
- Tongji Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Lacidophilin is a live biotherapeutic product (LBP) consisting of live *Lactobacillus* (typically *Lactobacillus acidophilus*). It is used as a probiotic to restore the natural microbial flora of the vaginal and endometrial environments. In clinical applications, particularly in reproductive medicine, it is administered vaginally to correct dysbiosis, which is characterized by a decrease in *Lactobacillus* species and an overgrowth of pathogenic bacteria. By producing lactic acid, hydrogen peroxide, and bacteriocins, lacidophilin helps maintain an acidic environment (low pH) that is conducive to healthy tissue function and successful embryo implantation. It is currently being evaluated in clinical trials for its potential to improve pregnancy rates in women experiencing recurrent implantation failure (RIF) during assisted reproductive technology (ART) procedures like IVF and ICSI.
- Brand names
- Dingjunsheng
- Other names
- lacidophilinumlactobacillus acidophilusLive Lactobacillus Capsules for Vaginal Use
Beyond the preview
Go deeper on lacidophilin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacidophilin.